Cite
HARVARD Citation
Bodemer, C. et al. (2021). Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52‐week results from a Phase 3 double‐blind randomized, controlled trial. Journal of the European Academy of Dermatology and Venereology. pp. 938-947. [Online].